GlassScriptPhysician profile
David William Huffman
NPI 1063860526
$50,361.45
in general payments reported to CMS, 2019-2025
23 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,419 · 2022: $1,206 · 2023: $13K · 2024: $11K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Food and Beverage: $10K · Travel and Lodging: $1,162 · Education: $74.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,325.00 |
| Food and Beverage | $10,174.13 |
| Travel and Lodging | $1,162.03 |
| Education | $74.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $40,961.86 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,284.64 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $1,077.73 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $974.47 | 2021-2025 | Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $960.44 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $718.99 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $700.19 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $677.33 | 2024-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $649.93 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $530.35 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $417.92 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $352.54 | 2022-2025 | Uzedy, Austedo, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $240.32 | 2021-2022 | |
| Tris Pharma INC | $209.99 | 2024-2025 | Dyanavel Xr |
| Corium, LLC | $180.15 | 2022-2023 | Azstarys |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $146.20 | 2021-2025 | Trintellix |
| Indivior INC. | $111.22 | 2022-2025 | Perseris, Sublocade |
| Idorsia Pharmaceuticals US INC | $43.10 | 2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $42.25 | 2022 | |
| Noven Therapeutics, LLC | $28.50 | 2023 | Xelstrym |
| Janssen Biotech, INC. | $21.16 | 2023 | |
| Almatica Pharma LLC | $19.35 | 2025 | Loreev Xr |
| Eisai INC. | $12.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Huffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.